Company: OPGN
Filing Date: 2025-08-21
Form Type: 10-K
Source: 0001829126-25-006628
Chunk: 2282

Company: OPGEN INC
Filing Date: 2025-08-21
Form: 10-K
Item: Item 15
Chunk 2282
---
210,648
    )

    -

    Payments on debt

    -

    (3,914,490
    )
  
    Payments on finance lease obligations

    (280
    )

    (3,364
    )
  
    Net cash provided by financing activities

    5,028,574

    8,373,314

    Effects of exchange rates on cash

    -

    265,066

    Net increase (decrease) in cash, cash equivalents and restricted cash

    158,830

    (6,481,574
    )
  
    Cash and cash equivalents and restricted cash at beginning of year

    1,454,085

    7,935,659

    Cash and cash equivalents and restricted cash at end of year
     
    $
    1,612,915

    $
    1,454,085

    Supplemental disclosure of cash flow information

    Cash paid for interest
     
    $
    7,555

    $
    1,424,140

    Supplemental disclosures of non-cash investing and financing activities

    Settlement of deferred compensation and severance
     
    $
    1,333,285

    $
    -

    Issuance of common stock upon conversion of preferred stock
     
    $
    2,950,217

    $
    -

    Right-of-use assets acquired through operating leases
     
    $
    -

    $
    801,321

    Purchased equipment not yet paid for
     
    $
    -

    $
    108,715

See accompanying notes to consolidated financial statements.

F-8

OpGen, Inc.

Notes to Consolidated Financial Statements

Note 1 – Organization

OpGen, Inc. (“OpGen” or the “Company”) was incorporated in Delaware in 2001. In April 2020, OpGen completed a business combination transaction with Curetis N.V., a public company with limited liability under the laws of the Netherlands, pursuant to which the Company acquired all the shares of Curetis GmbH, a private limited liability company organized under the laws of the Federal Republic of Germany (“Curetis GmbH”), and certain other assets and liabilities of Curetis N.V., including Ares Genetics GmbH (“Ares Genetics”), a wholly-owned subsidiary of Curetis GmbH (together, “Curetis”).

From inception until November 2023, OpGen operated as